Using the Food and Drug Administration's Sentinel System for Surveillance of TB Infection

    Basic Details
    Date
    Thursday, December 1, 2022
    Type
    Publication
    Description

    We examined patterns in care for individuals treated for latent TB infection (LTBI) in the US Food and Drug Administration's Sentinel System.

    Using administrative claims data, we identified patients who filled standard LTBI treatment prescriptions during 2008–2019. In these cohorts, we assessed LTBI testing, clinical management, and treatment duration.

     

    Author(s)

    Kristine M. Schmit, William L. Walker, Emily C. Welch, Laura A. Vonnahme, Amish Talwar, Michael Nguyen, Danijela Stojanovic, Adam J. Langer, Noelle M. Cocoros

    Corresponding Author

    William L. Walker; Surveillance, Epidemiology, and Outbreak Investigations Branch, Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA.

    Email: lxq4@cdc.gov